Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Active Surveillance of Metastatic Renal Cell Carcinoma
  2. Comprehensive Genomic Profiling of Metastatic Collecting Duct Carcinoma, Renal Medullary Carcinoma, and Clear Cell RCC
  3. First-Line Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma
  4. Pegilodecakin as Monotherapy or in Combination With Anti–PD-1 or TKI in Heavily Pretreated Patients With Advanced RCC
  5. Circulating Cytokines Associated With Clinical Response to Systemic Therapy in Metastatic RCC
  6. Predicting Disease Recurrence, Progression, and Overall Survival Following Surgical Resection for High-Risk RCC
  7. Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcome in Subtypes of RCC
  8. Nivolumab Plus Cabozantinib for Patients With Advanced RCC With Sarcomatoid Histology
  9. Survival in Patients Treated With First-Line ICIs Plus TKIs for Renal Cell Carcinoma
  10. Combination Antiangiogenic TKI/ICI Therapy in Metastatic Renal Cell Carcinoma

Elsewhere

Recently Updated